Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
| Author | |
|---|---|
| Abstract |
:
Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors. |
| Year of Publication |
:
2018
|
| Journal |
:
Cancer chemotherapy and pharmacology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0344-5704
|
| URL |
:
https://dx.doi.org/10.1007/s00280-018-3521-z
|
| DOI |
:
10.1007/s00280-018-3521-z
|
| Short Title |
:
Cancer Chemother Pharmacol
|
| Download citation |
